崩了！突然，爆雷

Core Viewpoint - Novo Nordisk's stock plummeted over 20% following the announcement of a new CEO and a downward revision of its annual sales and profit guidance due to weak growth expectations for its weight loss drug Wegovy in the U.S. market [1][2] Group 1: Company Performance - Novo Nordisk lowered its sales growth forecast for the year to 8% to 14%, down from the previous target of 13% to 21% [1] - The company also revised its operating profit growth expectations to 10% to 16%, compared to earlier projections of 21% and 24% [1] - Following the announcement, Novo Nordisk's market capitalization decreased by over $60 billion [1] Group 2: Market Competition - The company faces increasing competition from Eli Lilly's weight loss drug Zepbound and the presence of cheaper generic versions of Wegovy in the U.S. market [1][2] - Novo Nordisk plans to combat the impact of generics through legal actions and by investing in direct-to-consumer marketing efforts [1] Group 3: Leadership Changes - Maziar Mike Doustdar has been appointed as the new CEO, replacing Lars Fruergaard Jorgensen, who was unexpectedly removed in May [1][2] - The leadership change is part of the company's strategy to regroup after a series of setbacks [2]